Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016 (2016), Article ID 2475631, 14 pages
http://dx.doi.org/10.1155/2016/2475631
Research Article

High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis

1Takara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden
2Novo Nordisk A/S, Stem Cell Development, 2880 Bagsværd, Denmark
3Horizon Discovery Ltd, 7100 Cambridge Research Park, Waterbeach, Cambridge CB25 9TL, UK
4Systems Biology Research Center, School of Bioscience, University of Skövde, 541 28 Skövde, Sweden
5Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, 171 77 Stockholm, Sweden
6AstraZeneca R&D, GMD CVMD GMed, 431 83 Mölndal, Sweden
7NovaHep AB, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden

Received 30 July 2015; Revised 7 October 2015; Accepted 13 October 2015

Academic Editor: Toon van Veen

Copyright © 2016 Arvind Pradip et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Russmann, G. A. Kullak-Ublick, and I. Grattagliano, “Current concepts of mechanisms in drug-induced hepatotoxicity,” Current Medicinal Chemistry, vol. 16, no. 23, pp. 3041–3053, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Pandit, T. Sachdeva, and P. Bafna, “Drug-induced hepatotoxicity: a review,” Journal of Applied Pharmaceutical Science, vol. 2, no. 5, pp. 233–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Smith, “Tools for drug discovery: tools of the trade,” Nature, vol. 446, no. 7132, pp. 219–222, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Sivaraman, J. K. Leach, S. Townsend et al., “A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction,” Current Drug Metabolism, vol. 6, no. 6, pp. 569–591, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Hill, N. Mesens, M. Steemans, J. J. Xu, and M. D. Aleo, “Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development,” Drug Metabolism Reviews, vol. 44, no. 1, pp. 127–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Chalasani and E. Björnsson, “Risk factors for idiosyncratic drug-induced liver injury,” Gastroenterology, vol. 138, no. 7, pp. 2246–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. O'Brien, W. Irwin, D. Diaz et al., “High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening,” Archives of Toxicology, vol. 80, no. 9, pp. 580–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Xu, D. Diaz, and P. J. O'Brien, “Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential,” Chemico-Biological Interactions, vol. 150, no. 1, pp. 115–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. Xu, P. V. Henstock, M. C. Dunn, A. R. Smith, J. R. Chabot, and D. de Graaf, “Cellular imaging predictions of clinical drug-induced liver injury,” Toxicological Sciences, vol. 105, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. F. A. Brandon, C. D. Raap, I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, “An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons,” Toxicology and Applied Pharmacology, vol. 189, no. 3, pp. 233–246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Kia, R. L. C. Sison, J. Heslop et al., “Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?” British Journal of Clinical Pharmacology, vol. 75, no. 4, pp. 885–896, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Jensen, J. Hyllner, and P. Björquist, “Human embryonic stem cell technologies and drug discovery,” Journal of Cellular Physiology, vol. 219, no. 3, pp. 513–519, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Czyz, C. Wiese, A. Rolletschek, P. Blyszczuk, M. Cross, and A. M. Wobus, “Potential of embryonic and adult stem cells in vitro,” Biological Chemistry, vol. 384, no. 10-11, pp. 1391–1409, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ulvestad, P. Nordell, A. Asplund et al., “Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells,” Biochemical Pharmacology, vol. 86, no. 5, pp. 691–702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Holmgren, A.-K. Sjögren, I. Barragan et al., “Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes,” Drug Metabolism and Disposition, vol. 42, no. 9, pp. 1401–1406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Gómez-Lechón, L. Tolosa, J. V. Castell, and M. T. Donato, “Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project,” Toxicology in Vitro, vol. 24, no. 7, pp. 1879–1889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Tolosa, S. Pinto, M. T. Donato et al., “Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs,” Toxicological Sciences, vol. 127, no. 1, pp. 187–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. T. Donato, A. Martínez-Romero, N. Jiménez et al., “Cytometric analysis for drug-induced steatosis in HepG2 cells,” Chemico-Biological Interactions, vol. 181, no. 3, pp. 417–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. A. Chatman, D. Morton, T. O. Johnson, and S. D. Anway, “A strategy for risk management of drug-induced phospholipidosis,” Toxicologic Pathology, vol. 37, no. 7, pp. 997–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. T. Donato, L. Tolosa, N. Jiménez, J. V. Castell, and M. J. Gómez-Lechón, “High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay,” Journal of Biomolecular Screening, vol. 17, no. 3, pp. 394–400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Reasor, K. L. Hastings, and R. G. Ulrich, “Drug-induced phospholipidosis: issues and future directions,” Expert Opinion on Drug Safety, vol. 5, no. 4, pp. 567–583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Lettéron, A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre, “Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice,” Hepatology, vol. 38, no. 1, pp. 133–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Jaeschke, G. J. Gores, A. I. Cederbaum, J. A. Hinson, D. Pessayre, and J. J. Lemasters, “Mechanisms of hepatotoxicity,” Toxicological Sciences, vol. 65, no. 2, pp. 166–176, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Labbe, D. Pessayre, and B. Fromenty, “Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies,” Fundamental & Clinical Pharmacology, vol. 22, no. 4, pp. 335–353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Dong, P. Saikumar, J. M. Weinberg, and M. A. Venkatachalam, “Calcium in cell injury and death,” Annual Review of Pathology, vol. 1, pp. 405–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Grattagliano, L. Bonfrate, C. V. Diogo, H. H. Wang, D. Q. H. Wang, and P. Portincasa, “Biochemical mechanisms in drug-induced liver injury: certainties and doubts,” World Journal of Gastroenterology, vol. 15, no. 39, pp. 4865–4876, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Pessayre, B. Fromenty, A. Berson et al., “Central role of mitochondria in drug-induced liver injury,” Drug Metabolism Reviews, vol. 44, no. 1, pp. 34–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang, and W. Tong, “FDA-approved drug labeling for the study of drug-induced liver injury,” Drug Discovery Today, vol. 16, no. 15-16, pp. 697–703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Parmentier, G. L. Truisi, K. Moenks et al., “Transcriptomic hepatotoxicity signature of chlorpromazine after short- and long-term exposure in primary human sandwich cultures,” Drug Metabolism and Disposition, vol. 41, no. 10, pp. 1835–1842, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Lewis, W. E. Dennis, J. Hadix, and D. A. Jackson, “Analysis of secreted proteins as an in vitro model for discovery of liver toxicity markers,” Journal of Proteome Research, vol. 9, no. 11, pp. 5794–5802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. W. G. E. J. Schoonen, J. A. D. M. de Roos, W. M. A. Westerink, and E. Débiton, “Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II Mechanistic assays on NAD(P)H, ATP and DNA contents,” Toxicology in Vitro, vol. 19, no. 4, pp. 491–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. W. M. A. Westerink and W. G. E. J. Schoonen, “Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells,” Toxicology in Vitro, vol. 21, no. 8, pp. 1581–1591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Wilkening, F. Stahl, and A. Bader, “Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties,” Drug Metabolism and Disposition, vol. 31, no. 8, pp. 1035–1042, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo, “The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics,” Chemico-Biological Interactions, vol. 168, no. 1, pp. 66–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Szabo, Z. Veres, Z. Baranyai, F. Jakab, and K. Jemnitz, “omparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity,” PLoS ONE, vol. 8, no. 3, Article ID e59432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Anthérieu, C. Chesné, R. Li, C. Guguen-Guillouzo, and A. Guillouzo, “Optimization of the HepaRG cell model for drug metabolism and toxicity studies,” Toxicology in Vitro, vol. 26, no. 8, pp. 1278–1285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Anthérieu, A. Rogue, B. Fromenty, A. Guillouzo, and M.-A. Robin, “Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells,” Hepatology, vol. 53, no. 6, pp. 1895–1905, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. H. H. J. Gerets, K. Tilmant, B. Gerin et al., “Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins,” Cell Biology and Toxicology, vol. 28, no. 2, pp. 69–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. T. B. Andersson, K. P. Kanebratt, and J. G. Kenna, “The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human,” Expert Opinion on Drug Metabolism & Toxicology, vol. 8, no. 7, pp. 909–920, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Atiq, J. C. Davis, L. W. Lamps, S. S. Beland, and J. E. Rose, “Amiodarone induced liver cirrhosis. Report of two cases,” Journal of Gastrointestinal and Liver Diseases, vol. 18, no. 2, pp. 233–235, 2009. View at Google Scholar · View at Scopus